Rheumatoid Arthritis Therapeutics Market at Worth USD 33,958.4 Million at 4.6% CAGR Forecast by 2025

According to the Centers for Disease Control and Prevention (CDC), nearly 0.6% of population in the U.S. suffer from rheumatoid arthritis.  Rheumatic arthritis is more common among the aged population, finds Fortune Business Insights in a report, titled “Rheumatoid Arthritis Therapeutics Market: Global Market Analysis, Insights and Forecast 2018-2025” according to this report, the Global Rheumatoid Arthritis Therapeutics Market is anticipated to worth US$ 33,958.4 Mn by 2025 from US$ 23,822.5 Mn in 2017 with a steady CAGR of 4.6%.

Market Players Leaving No Stone Unturned to Stay Ahead in Competition 

Competition in the market is intense with manufacturers offering new and cost effective products. Owing to the price-sensitive nature of various regions, a few market players are trying to introduce both branded and generic drugs in order to gain competitive advantage Increasing investments in research and development for the discovery of novel therapeutics is also propelling the market globally.

According to the report, the dominant share of the market was held by the top ten companies. These companies together held nearly 80.0% of the global market with AbbVie Inc. in the lead. Strategies such as increasing investments, increasing focus on research and development activities, strategic collaborations, new product launches, and others are adopted by major players in order to be at the top of the market and give a tough competition to others.

Some of the key players operating in the global market for rheumatoid arthritis treatment market are Amgen Inc., CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., Johnson & Johnson Services, Bristol-Myers Squibb Company, UCB S.A., and Gilead Sciences, Inc.

Technological Advancements and Discovery of New Treatments to Drive Market 

Because the incidence of rheumatoid arthritis is more common among aged people, the rising geriatric population will boost sales in the market over the forecast period. The increasing prevalence of rheumatology diseases such as infectious arthritis, gout, bursitis, osteoporosis, osteoarthritis, Crohn’s Disease, and others will also fuel the demand for rheumatoid arthritis treatment.

Besides this, the technological advancements witnessed in the healthcare sector and launch of novel drugs in the pharmaceutical industries are enabling growth in the global rheumatoid arthritis therapeutics market.

However, with the launch of biosimilars for treatment of rheumatoid arthritis, may pose challenges to the market. Moreover, looming patent expiry of blockbuster drugs may hinder the growth of the rheumatoid arthritis therapeutics market.

This, coupled with the introduction of generic drugs, is expected to hamper growth witnessed in the market. Nevertheless, the increasing expenditure on healthcare infrastructure and government support in form of launching favorable health reimbursement policies are likely to offer lucrative growth opportunities in the coming years. 

Expansion of Healthcare Infrastructure will Enable Growth in Asia Pacific

Regionally, the global market for rheumatoid arthritis therapeutics is dominated by North America. Its dominance is attributed to the presence of major players in the region, coupled with the availability of proper medical facilities. In 2017, the North America market for rheumatoid arthritis therapeutics was valued at US$ 9,929.6 Mn. This is owing to the increasing prevalence of rheumatoid arthritis and other chronic disorders in this region.

However, the market in Asia Pacific is expected to show growth at a faster pace in the coming years, because of the rising awareness about rheumatic arthritis and various preventive measures. Besides this, the expansion of healthcare infrastructure and increasing access to advanced medical facilities will support the market’s expansion in China and India.

Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-therapeutics-market-100488

SEGMENTATION